R G McAllister Jr
Overview
Explore the profile of R G McAllister Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kraus C, Baldwin A, Curro F, McAllister Jr R
Curr Drug Saf
. 2015 May;
10(2):159-64.
PMID: 25986037
In June, 2012 the United States Food and Drug Administration (FDA) developed a "blueprint" for prescriber education as a means of directing Certified Medical Education (CME) activities that included content...
2.
McAllister Jr R, Franson T, Kraus C
Curr Drug Saf
. 2013 May;
8(1):17-24.
PMID: 23656444
Pharmaceutical agents are prescribed to produce a therapeutic effect, but safety concerns require constant attention to the benefit:risk relationship inherent in their use and the needs of the individual patient....
3.
Kraus C, Baldwin A, McAllister Jr R
Curr Drug Saf
. 2013 May;
8(1):11-6.
PMID: 23656443
The US Food and Drug Administration (FDA) requires risk communication as an element of Risk Evaluation and Mitigation Strategies (REMS) to alert and educate healthcare providers about severe toxicities associated...
4.
Hamann S, McAllister Jr R
J Cardiovasc Pharmacol
. 1994 Jan;
23(1):31-6.
PMID: 7511732
The cardiovascular actions of combined intravenous (i.v.) diltiazem and propranolol were studied in barbiturate-anesthetized dogs. When given alone, diltiazem increased cardiac output (CO) and P-R interval duration (P-R) while decreasing...
5.
Swartz S, Gonasun L, McAllister Jr R, Thadani U
Cardiovasc Drugs Ther
. 1990 Apr;
4(2):413-7.
PMID: 2149512
Isradipine is a dihydropyridine calcium-entry blocking agent with pronounced vasodilator activity and no significant cardiac effects at clinical doses, a desirable profile for an antihypertensive drug. Prazosin, a post-junctional alpha-adrenoceptor...
6.
Clifton G, Booth D, Hobbs S, Boucher B, FOSTER T, McAllister Jr R, et al.
Am Heart J
. 1990 Feb;
119(2 Pt 1):283-90.
PMID: 2301217
The relative extent of the vasodilator versus direct negative inotropic effects of nifedipine was studied in 15 male patients with documented coronary artery disease and normal left ventricular function. At...
7.
Hamann S, Kaltenborn K, McAllister Jr R
J Cardiovasc Pharmacol
. 1987 Aug;
10(2):182-9.
PMID: 2441169
The relationships between plasma drug concentrations and cardiovascular effects during combined administration of nifedipine and propranolol were evaluated in dogs anesthetized with thiopental. Three received small intravenous (i.v.) doses of...
8.
Hamann S, Kaltenborn K, McAllister Jr R
Pharmacology
. 1987 Jan;
34(6):326-36.
PMID: 3659118
Combined administration of verapamil, a phenylalkylamine calcium-entry antagonist, with a pure beta-adrenoceptor blocker, propranolol, produces profound cardiovascular depression associated with decreased hepatic clearance of both drugs. We have therefore studied...
9.
McAllister Jr R
Am J Med
. 1986 Dec;
81(6A):2-5.
PMID: 3799661
Nifedipine is frequently administered by the sublingual route to provide rapid onset of intense effect, especially in patients in whom urgent reduction of elevated blood pressure is indicated. Previously available...
10.
McAllister Jr R, Schloemer G, Hamann S
Am J Cardiol
. 1986 Feb;
57(7):16D-21D.
PMID: 3513512
The calcium-entry antagonists verapamil, diltiazem and nifedipine (and their analogs) are all eliminated by hepatic metabolism and the rate of disposition is dependent on the rate of liver blood flow....